Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations and price targets for Rapport Therapeutics and Unicycive Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rapport Therapeutics | 1 | 0 | 10 | 2 | 3.00 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Rapport Therapeutics currently has a consensus price target of $62.86, indicating a potential upside of 27.42%. Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 251.12%. Given Unicycive Therapeutics’ higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Rapport Therapeutics.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rapport Therapeutics | N/A | N/A | -$111.48 million | ($3.04) | -16.23 |
| Unicycive Therapeutics | $680,000.00 | 218.70 | -$26.56 million | ($1.75) | -3.05 |
Unicycive Therapeutics has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
40.4% of Unicycive Therapeutics shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Rapport Therapeutics and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rapport Therapeutics | N/A | -29.02% | -27.37% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Volatility & Risk
Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.
About Rapport Therapeutics
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
